Table S3.
Results from combination therapy NMA study arm level (patient characteristics) covariate analysis for American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 end point
| OR v DMARD (95% CrI)‡ | |||
|---|---|---|---|
|
|
|||
| ACR 20 | ACR 50 | ACR 70† | |
| Base case: random effects | |||
| ABA 10 mg/kg/4 weeks + DMARD | 3.255 (2.056, 5.159)‡ | 3.633 (2.093, 6.341)‡ | 3.954 (1.974, 8.8)‡ |
| ADA 40 mg/2 weeks + DMARD | 3.439 (2.187, 5.303)‡ | 3.87 (2.303, 6.598)‡ | 3.868 (1.91, 7.83)‡ |
| CZP 200 mg/2 weeks + DMARD | 11.06 (6.055, 21.06)‡ | 9.773 (4.604, 22.65)‡ | 13.18 (4.489, 43.5)‡ |
| ETN 2 × 25 mg/week + DMARD | 9.341 (4.845, 19.29)‡ | 11.15 (4.947, 27.95)‡ | 20.69 (4.921, 158.6)‡ |
| GOL 50 mg/4 weeks + DMARD | 3.387 (1.604, 6.863)‡ | 4.917 (2.051, 12.34)‡ | 4.988 (1.401, 18.28)‡ |
| INF 3 mg/kg/8 weeks + DMARD | 3.347 (2.271, 4.983)‡ | 3.602 (2.246, 5.924)‡ | 3.694 (2.021, 7.307)‡ |
| RTX 2 × 1000 mg + DMARD | 3.716 (1.915, 7.418)‡ | 4.103 (1.821, 9.73)‡ | 2.644 (0.909, 8.387) |
| TOC 8 mg/kg/4 weeks + DMARD | 4.399 (2.704, 7.125)‡ | 5.401 (2.911, 9.561)‡ | 7.656 (3.442, 16.5)‡ |
| Covariate analysis^ | |||
| ABA 10 mg/kg/4 weeks + DMARD | 3.242 (2.181, 4.765)‡ | 3.626 (2.643, 5.051)‡ | 4.187 (2.627, 7.196)‡ |
| ADA 40 mg/2 weeks + DMARD | 4.151 (2.662, 6.658)‡ | 5.221 (3.281, 8.649)‡ | 4.774 (2.312, 10.8)‡ |
| CZP 200 mg/2 weeks + DMARD | 11.34 (6.8, 20.36)‡ | 10.8 (6.096, 22.74)‡ | 15.17 (6.535, 41.99)‡ |
| ETN 2 × 25 mg/week + DMARD | 8.183 (4.108, 17.72)‡ | 9.377 (4.661, 23.88)‡ | 23.06 (5.343, 150.1)‡ |
| GOL 50 mg/4 weeks + DMARD | 3.674 (1.802, 6.893)‡ | 5.491 (2.821, 10.48)‡ | 6.67 (2.42, 18.11)‡ |
| INF 3 mg/kg/8 weeks + DMARD | 3.334 (2.418, 4.616)‡ | 3.634 (2.692, 4.763)‡ | 4.019 (2.708, 6.159)‡ |
| RTX 2 × 1000 mg + DMARD | 3.634 (2.072, 6.462)‡ | 3.913 (2.341, 7.101)‡ | 2.42 (1.149, 5.519)‡ |
| TOC 8 mg/kg/4 weeks + DMARD | 4.466 (2.991, 6.703)‡ | 5.927 (4.274, 8.365)‡ | 9.456 (5.74, 16.06)‡ |
| Coefficients (on log scale)‡ | Median (95% CrI) | ||
| βage: Age at baseline (average for study arm) | 0.016 (−0.05, 0.079) | 0.051 (−0.01, 0.115) | 0.134 (0.037, 0.229)† |
| βduration: Duration of disease (average for study arm) | 0.025 (−0.053, 0.104) | 0.074 (0.005, 0.149)† | 0.099 (−0.002, 0.218) |
Notes:
Results centered at study-arm mean (mean age across study arms = 52.43 years, mean disease duration = 7.86 years);
licensed combination had significantly higher odds (based on the 95% CrI) compared to DMARD alone;
for the ACR 70 network meta-analysis, a continuity correction (0.5) was applied to the data; the coefficients were not statistically significant except for + (longer disease duration was associated with higher odds of ACR 50; higher age was associated with higher odds of ACR 70).
Abbreviations: ABA, abatacept; ADA, adalimumab; ANA, anakinra; CrI, credible interval (Bayesian probability interval); CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug (MTX or SUL); ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; OR, odds ratio; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.